Vendor Intelligence Report: Dankang BioHealth
Published 12 Nov 2026. 41-page investigative report on who is behind Dankang BioHealth: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Across 96 Finnrick lab tests, Dankang BioHealth records 57 pass / 39 fail, for an overall pass rate of 59%. The result is not a simple vendor-wide yes or no. GHK-Cu is the strongest signal, retatrutide is the deepest and more defensible buying lane, while NAD+ and MOTS-c sit at the weak end of the catalog. The full report shows how the picture changes under stricter scoring and why exact-batch proof matters.
The company presentation is much less settled than the factory language suggests. The two Dankang domains date to late 2025, while the site carries older template artifacts and review dates that predate the domains. The About page claims a Shenzhen manufacturer, Class 10,000 workshop, 800 kg annual capacity, patents and The Lancet-published standards, but the public-source checks did not verify a legal entity, factory-level address, licence, patent portfolio or named technical decision-maker.
Authentication is another major theme. Dankang operates across two near-identical domains, rotating sales personas, multiple Hong Kong-facing contact numbers and a same-template storefront cluster. One published Janoshik retatrutide report verifies; another Janoshik code does not resolve. The report maps those paths rather than treating screenshots as proof.
The investigation also follows the promotion and recourse layer: Facebook funnel pages, unrelated parasite-SEO placements, recycled reviews, a Telegram channel with a sharp subscriber drop, Reddit non-delivery allegations and payment rails where buyer reversal rights vary sharply. There are positives: the main domains were renewed, the storefront is active and at least one third-party report is genuine. The risk is selective, product-specific and operational, not a blanket label.
Inside the full report:
- Per-product pass/fail rates and methodology-divergence charts for all 11 tested products
- RDAP, DNS, TLS and reverse-IP analysis of the Dankang storefront cluster
- Manufacturer-claim audit covering registry searches, patent claims, address claims and missing policies
- COA verification flow comparing the working Janoshik retatrutide report with the non-resolving code
- Facebook page cluster and parasite-SEO analysis with screenshots and ad-transparency checks
- Sales-persona roster diff, Telegram timeline, Reddit complaint review and payment-recourse assessment
Risk assessment
- Corporate identity and manufacturer-claim risk — high: No Shenzhen/HK entity, licence, patent number, Lancet citation, named director or factory-level address could be verified; site claims 8 patents, Class 10,000 workshop and 800 kg/year without identifiers.
- Product-specific quality risk in lower-performing peptides — high: Weak Finnrick records for NAD+ 25.95%, MOTS-c 28.91%, CJC-1295 29.99%, TB-500 37.42%, Tesamorelin 50.85% and BPC-157 52.05%; GHK-Cu 85.78%, Retatrutide 77.07% and Tirzepatide 71.56% are materially stronger.
- Fulfillment and buyer-recourse risk — high: Reddit allegations describe non-delivery, stalled tracking and dispute-cancellation pressure totaling at least $4,506+, while crypto, T/T and similar rails limit reversal options.
- Brand-authenticity and copycat/confusion risk — medium: Two similar domains, rotating sales personas, at least eight Facebook pages and multiple +852 numbers exist without an official channel, authorized-reseller or payment-account directory.
- COA verification risk — medium: One Janoshik retatrutide report verifies but the second published Janoshik code 200705 does not resolve; public COA coverage is batch-limited and incomplete.
- Promotion-integrity risk — medium: Facebook funnel pages and parasite-SEO articles recycle vendor-origin reviews without relationship disclosure; buyers cannot treat those search or social signals as independent.
- Controlled-substance catalog risk — medium: The catalog includes dermorphin, a controlled substance in some jurisdictions. No Dankang-specific CBP action was identified.